Franklin Resources Inc Bei Gene, Ltd. Transaction History

Franklin Resources Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $30,709 - $47,121	233 Added 9.19%	2,767 $374,000
Q2 2022 Aug 11, 2022	BUY	$121.11 - $216.05 $5,086 - $9,074	42 Added 1.69%	2,534 $410,000
Q1 2022 May 13, 2022	SELL	$146.52 - $269.56 $4,395 - $8,086	-30 Reduced 1.19%	2,492 $470,000
Q4 2021 Feb 11, 2022	SELL	$248.56 - $389.34 $39,521 - $61,905	-159 Reduced 5.93%	2,522 $684,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $457,516 - $738,955	1,833 Added 216.16%	2,681 $973,000
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $4,976 - $6,239	17 Added 2.05%	848 $291,000
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $1.4 Million - $2.05 Million	-5,374 Reduced 86.61%	831 $289,000
Q4 2020 Feb 10, 2021	BUY	$221.31 - $316.61 $1.12 Million - $1.61 Million	5,071 Added 447.18%	6,205 $1.6 Million
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $214,530 - $324,822	1,134 New	1,134 $325,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.